Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA)
Treatment of Oligometastatic Breast Cancer - a Randomised Phase 3 Trial Comparing Stereotactic Ablative Radiotherapy and Systemic Treatment With Systemic Treatment Alone as 1st Line Treatment
Sponsor: Azienda Ospedaliero-Universitaria Careggi
This NA trial investigates Breast Cancer Stage IV and Oligometastatic Disease and is currently actively recruiting participants. Azienda Ospedaliero-Universitaria Careggi leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Mar 2025 — Present [monthly]
Recruiting NA
-
Feb 2025 — Mar 2025 [monthly]
Recruiting NA
-
Sep 2024 — Feb 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Nov 2022 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jun 2022 — Nov 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Azienda Ospedaliero-Universitaria Careggi
- Centrallasarettet Västerås
- Gävle Hospital
- Haukeland University Hospital
- Karlstad Central Hospital
- Karolinska University Hospital
- Oslo University Hospital
- Region Örebro County
- Sahlgrenska University Hospital
- Skane University Hospital
- St. Olavs Hospital
- Sundsvall Hospital
- University Hospital of North Norway
- University Hospital, Umeå
- University of Stavanger
- Uppsala University Hospital
- Vastra Gotaland Region
For direct contact, visit the study record on ClinicalTrials.gov .